Bayer and Boryung are competing in the aspirin market

Aspirin Protect's 20 Billion Performance Strengthen

pay attention to accelerating growth of Astrix

Hanmi and Yuhan, 3.3 billion and 1.7 billion external

In the market for aspirin-based cardiovascular treatments, Bayer Aspirin Protect 100 mg was found to be the undisputed No.

 

1.

 

According to medical distribution performance data, Aspirin Protect recorded 18.8 billion won last year and is leading the market while maintaining the appearance of banding worth 20 billion won.

 

Aspirin Protect's sales in 2018, 2019, and 2020 are 22.5 billion, 19.1 billion, and 17.1 billion won and cumulative sales by 3Q in 2022 are 15 billion won, which is likely to surpass 20 billion won this year.

 

The second place was Boryung Biopharma's Astrix, which recorded 12.8 billion won in performance last year.

 

During the same period, Astrix's appearance is 15.4 billion won, 14.6 billion won, and 13.4 billion won, and the cumulative total until 3Q is 9.2 billion won, which is expected to generate similar sales to the previous year.

 

The market share of the two products was 45,31%, which dominated 76% of the market.

 

The third and fourth places are Hanmi Pharmaceutical and Yuhan Corporation aspirin, which recorded sales of 3.3 billion won and 1.7 billion won last year.

 

The market share of Hanmi and Yuhan is formed at about 8/4%.

 

Products ranked 5th to 10th show performance of around 100 million to 300 million, and the fact that they are virtually meaningless competition is another characteristic of the aspirin cardiovascular treatment market.

 

The drug prices of Aspirin Protect and Astrix, which were approved by the Ministry of Food and Drug Safety in 2001 and 2009, are 77 won each, the highest registered price among the same-component drugs, and the insurance price of Aspirin of Hanmi and Yuhan is 61 won per person.

 

Aspirin, a representative antiplatelet drug, prevents coronary artery occlusion by inhibiting cyclooxygenase in the arachidonic acid pathway and inhibiting the production of thromboxane A2, a thrombus-causing substance.

 

It lowers the morbidity and mortality of angina at a dose of 75 mg to 325 mg per day and is also used for other myocardial infarctions and strokes.

 

In the case of secondary prevention of ischemic stroke, aspirin and clopidogrel are used, and aspirin and warfarin are prescribed to prevent stroke by atrial fibrillation.

 

According to the CHEST guidelines, appropriate preventive drugs can be administered depending on the presence or absence of a history of stroke, transient ischemia, and the number of risk factors.

 

For aspirin allergy patients, Clopidogrel, Ticagrelor, Prasugrel, etc.

 

can be used.

 

Meanwhile, aspirin is used as a fever and anti-inflammatory painkiller for high doses (250 mg, 300 mg, 500 mg), and low doses (75 mg, 81 mg, 100 mg) are used to prevent blood clots.